GSK-201755

Study Sponsor: GSK

Study Title

A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate

Medicine or Vaccine (generic name)

otilimab

Sponsor Identification Number

201755

Trial Registry Identification Number(#'s)

NCT02504671

Medical Condition

Arthritis, Rheumatoid

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=201755

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT02504671

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2014-003453-34

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

November 2020